Cargando…

TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy

Immunotherapy for cancer is making impressive strides at improving survival of a subset of cancer patients. To increase the breadth of patients that benefit from immunotherapy, new strategies that combat the immunosuppressive microenvironment of tumors are needed. Phosphatidylserine (PS) signaling i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dayoub, Adam S., Brekken, Rolf A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036251/ https://www.ncbi.nlm.nih.gov/pubmed/32087708 http://dx.doi.org/10.1186/s12964-020-0521-5

Ejemplares similares

Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer
por: Belzile, Olivier, et al.
Publicado: (2018)

TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting
por: Peeters, Marlies J. W., et al.
Publicado: (2019)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
por: Du, Wenwen, et al.
Publicado: (2017)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
por: Kuang, Zhihui, et al.
Publicado: (2020)

TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress
por: Shen, Xinyuan, et al.
Publicado: (2022)

Identification of Tam41 maintaining integrity of the TIM23 protein translocator complex in mitochondria
por: Tamura, Yasushi, et al.
Publicado: (2006)

Targeting the TAM Receptors in Leukemia
por: Huey, Madeline G., et al.
Publicado: (2016)

TAM Receptor Inhibition–Implications for Cancer and the Immune System
por: Aehnlich, Pia, et al.
Publicado: (2021)

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
por: Sauer, Natalia, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Targeting Gas6/TAM in cancer cells and tumor microenvironment
por: Wu, Guiling, et al.
Publicado: (2018)

The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy
por: Paolino, Magdalena, et al.
Publicado: (2016)

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
por: Myers, Kayla V., et al.
Publicado: (2019)

TAM receptors, Phosphatidylserine, inflammation, and Cancer
por: Burstyn-Cohen, Tal, et al.
Publicado: (2019)

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy
por: Mikolajczyk, Agata, et al.
Publicado: (2022)

Tim-3 finds its place in the cancer immunotherapy landscape
por: Acharya, Nandini, et al.
Publicado: (2020)

Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response
por: Davra, Viralkumar, et al.
Publicado: (2016)

An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy
por: Li, Yan-Ruide, et al.
Publicado: (2022)

Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1
por: Desai, Tanvi J., et al.
Publicado: (2016)

The TAM family as a therapeutic target in combination with radiation therapy
por: Tormoen, Garth W., et al.
Publicado: (2017)

TAM receptors in cardiovascular disease
por: McShane, Lucy, et al.
Publicado: (2019)

New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis
por: Larionova, Irina, et al.
Publicado: (2021)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma
por: Luo, Hong, et al.
Publicado: (2023)

The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview
por: Wium, Martha, et al.
Publicado: (2018)

Molecular insights of Gas6/TAM in cancer development and therapy
por: Wu, Guiling, et al.
Publicado: (2017)

Inhibiting Growth of Human Triple-Negative Breast Cancer Cells by Activating Mutant p53 Protein Alone or in Combination With a Phosphatidylserine-Targeting Antibody
por: Liang, Yayun, et al.
Publicado: (2021)

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Yang, Riyao, et al.
Publicado: (2021)

The Gas6/TAM System and Multiple Sclerosis
por: Bellan, Mattia, et al.
Publicado: (2016)

Influence of the Hippo-YAP signalling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment
por: Yang, Wenjie, et al.
Publicado: (2020)

TAM receptors Tyro3 and Mer as novel targets in colorectal cancer
por: Schmitz, Robin, et al.
Publicado: (2016)

The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy
por: Yang, Qiyao, et al.
Publicado: (2020)

Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities
por: Lew, Erin D, et al.
Publicado: (2014)

Tumour-Associated Macrophages (TAMs) in Colon Cancer and How to Reeducate Them
por: Yahaya, M. A. F., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c6j2343su32hobv6hjcsglbqlo